Skip to main content
. 2020 Oct 15;10(4):329–339.

Table 1.

Clinical, laboratory and anatomical data of controls and patients with chronic coronary syndrome

Controls Patients with CCS p-value
(n=26) (n=68)
Clinical data
    Age, years 61.3 (9.4) 64.8 (9.3) 0.099
    Male, n (%) 23 (88.5) 61 (89.7) 1.000
    Hypertension, n (%) 14 (53.8) 64 (94.1) <0.001
    Dyslipidemia, n (%) 18 (69.2) 65 (95.6) <0.001
    Diabetes mellitus, n (%) 3 (11.5) 29 (42.6) 0.007
    Smoking history (current or past), n (%) 6 (23.1) 37 (54.4) 0.006
    Previous coronary artery bypass grafting, n (%) 0 (0.0) 23 (33.8) <0.001
    Left ventricular ejection fraction > 50%, n (%) 26 (100.0) 68 (100.0) -
    Antiplatelet agent, n (%) 6 (23.1) 66 (97.1) <0.001
    Statin therapy, n (%) 13 (50.0) 61 (89.7) <0.001
Laboratory data
    Hemoglobin, g/dL 13.9 (1.3) 13.6 (1.6) 0.380
    Leukocyte count, 10^9/L 6.4 (1.7) 7.6 (1.8) 0.012
    Neutrophil count, 10^9/L 3.5 (1.5) 4.4 (1.5) 0.010
    Lymphocyte count, 10^9/L 2.0 (0.5) 2.1 (0.8) 0.722
    Neutrophil/lymphocyte ratio 1.9 (0.7) 2.4 (1.1) 0.029
    Platelet count, 10^9/L 230.1 (58.8) 222.6 (51.1) 0.546
    Fasting glycaemia, mg/dL 95.3 (35.1) 112.7 (52.5) 0.124
    Percentage of glycosylated hemoglobin 5.8 (1.2) 6.4 (1.5) 0.014
    Creatinine, mg/dL 0.8 (0.2) 1.0 (0.3) 0.001
    Total cholesterol, mg/dL 186.0 (50.7) 166.4 (45.9) 0.082
    LDL-cholesterol, mg/dL 111.3 (44.2) 100.9 (37.7) 0.261
    HDL-cholesterol, mg/dL 51.5 (13.1) 37.6 (9.1) <0.001
    Triglycerides, mg/dL 133.6 (50.9) 149.0 (55.8) 0.234
    C-reactive protein, mg/L 4.1 (2.0) 3.7 (1.7) 0.334
    sCD40L, ng/mL 4.0 (1.5) 5.9 (3.3) 0.018
Anatomical data
    Nr. of vessels with obstructive disease 0 (0.0) 2.9 (0.8) <0.001
    Nr. of obstructive lesions 0 (0.0) 4.0 (1.4) <0.001
    Gensini score 0 (0.0) 72.9 (42.5) <0.001

Data are expressed as mean (SD), except if otherwise specified. CCS - chronic coronary syndrome; HDL - high-density lipoprotein; LDL - low-density lipoprotein; Nr. - number; sCD40L - soluble CD40 ligand.